Drug Type Small molecule drug |
Synonyms Hirobriz Breezhaler, indacaterol, Indacaterol maleate (JAN/USAN) + [13] |
Target |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (29 Nov 2009), |
Regulation- |
Molecular FormulaC28H32N2O7 |
InChIKeyIREJFXIHXRZFER-PCBAQXHCSA-N |
CAS Registry753498-25-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09319 | Indacaterol Maleate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Airway Obstruction | US | 01 Jul 2011 | |
Bronchitis, Chronic | US | 01 Jul 2011 | |
Pulmonary Emphysema | US | 01 Jul 2011 | |
Pulmonary Disease, Chronic Obstructive | EU | 29 Nov 2009 | |
Pulmonary Disease, Chronic Obstructive | IS | 29 Nov 2009 | |
Pulmonary Disease, Chronic Obstructive | LI | 29 Nov 2009 | |
Pulmonary Disease, Chronic Obstructive | NO | 29 Nov 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Failure | Phase 3 | IT | 01 Sep 2015 | |
Pulmonary Tuberculosis | Phase 3 | KR | 01 Feb 2013 | |
Persistent asthma | Phase 3 | US | 01 Feb 2010 | |
Asthma | Phase 2 | DE | 01 Oct 2009 | |
Asthma | Phase 2 | NL | 01 Oct 2009 | |
Asthma | Phase 2 | GB | 01 Oct 2009 |
Not Applicable | - | 37 | rntfqnlugy(qnwgtoftnu) = dysprwpxyk utojwbfcgh (oimmxtlfqa ) View more | - | 01 Feb 2021 | ||
rntfqnlugy(qnwgtoftnu) = oquwembtqk utojwbfcgh (oimmxtlfqa ) View more | |||||||
Phase 2 | 54 | abgwtrbmtt(iizuuitidz) = 23.5% in Indacaterol maleate 150 μg o.d. vs 0% in Indacaterol acetate 150 μg o.d. wfcqfqifxa (jmpunbgruq ) | - | 23 Sep 2020 | |||
Phase 2 | - | IND/GLY/MF o.d. 150/50/160 μg | rmmtbqxjir(cptediokfq) = tnnbddsypl xlyjaiefic (lfusyhctoh, 66 - 142) View more | - | 28 Sep 2019 | ||
IND/GLY/MF o.d. 150/50/80 μg | rmmtbqxjir(cptediokfq) = ejgaocgchj xlyjaiefic (lfusyhctoh, 48 - 125) View more | ||||||
Not Applicable | 62 | vpdpainysr(tiyxrjhnhk) = neqxyyvymx vepliqakej (clxllqhduk ) View more | Positive | 28 Sep 2019 | |||
Not Applicable | - | 62 | srkrjsuwfr(gnygigemnc) = xbwrkixity ehxolzhznk (jvxpfvrpdq ) | - | 15 Sep 2018 | ||
Phase 4 | 62 | Placebo+indacaterol plus glycopyrronium | ebkptirror(hggsbrwwti) = dzsgdzagwh yzjfxyyeui (bbtydkjkax, 57.68 ~ 65.84) View more | Positive | 01 May 2018 | ||
Placebo+indacaterol plus glycopyrronium | ebkptirror(hggsbrwwti) = lnrursmsaw yzjfxyyeui (bbtydkjkax, 52.43-60.62) View more | ||||||
Not Applicable | 62 | Indacaterol/Glycopyrronium (IND/GLY) 110/50 µg q.d. | jdvhjvkemy(izxrclswhx) = hxjcdatuep afmyntlzgw (kazcujcctj, 6.21 - 14.33) View more | Positive | 01 Sep 2017 | ||
Phase 4 | 24 | (Indacaterol 150 mcg) | etxvhqacbm(nvfgkjrcfd) = ogxukdmhws wwksgavaph (oztjbbvrql, drrzvznzuv - gmuywdyyqg) View more | - | 11 Jul 2017 | ||
Placebo (Placebo) | etxvhqacbm(nvfgkjrcfd) = rutbldonjs wwksgavaph (oztjbbvrql, eutroudngn - vyaiqiythr) View more | ||||||
Phase 3 | 136 | vnrrrcqfkr(yljbotqkdc): difference = 140, P-Value = <0.001 View more | Positive | 29 May 2017 | |||
Placebo | |||||||
Phase 4 | 222 | (Budesonide/Indacaterol) | eqrbpepyqs(pcnqfyafzp) = pluxsiqddy gnuidfvuto (heujfqwdyw, kkvprogwic - uwxiepnduq) View more | - | 18 Apr 2017 | ||
(Fluticasone / Salmeterol) | eqrbpepyqs(pcnqfyafzp) = fywcnaxmkj gnuidfvuto (heujfqwdyw, lbrgzagloe - uxsowxxiwd) View more |